Edaravone
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Edaravone: From ALS / Acute Ischemic Stroke to Heparin Cofactor 2 Deficiency
One-Sentence Summary
Edaravone is a free-radical scavenger (antioxidant) whose established clinical uses are amyotrophic lateral sclerosis (ALS) and acute ischemic stroke — though this candidate record has no formally sourced Taiwan license data confirming an original indication (data gap). The TxGNN model predicts it may be effective for Heparin Cofactor 2 Deficiency, an ultra-rare inherited coagulation disorder, but this prediction is currently supported by zero clinical trials and zero publications. A second, lower-ranked candidate (Factor V excess with spontaneous thrombosis) shows the same pattern of high model score but no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Taiwan license records (drug is not marketed in Taiwan); per evidence pack rationale, edaravone’s known clinical uses are ALS and acute ischemic stroke |
| Predicted New Indication | Heparin Cofactor 2 Deficiency |
| TxGNN Prediction Score | 99.47% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this record (flagged as a High-severity data gap). Based on known information, edaravone is a free-radical scavenger/antioxidant, with proven efficacy in ALS and acute ischemic stroke — conditions where oxidative stress contributes to neuronal injury.
Heparin cofactor 2 deficiency, by contrast, is a rare autosomal-dominant coagulation disorder caused by mutations in the SERPIND1 (HCF2) gene, leading to a prothrombotic tendency through impaired thrombin inhibition — a protein-function defect rather than an oxidative-stress-driven pathology.
The evidence pack’s own mechanistic assessment concludes that no known or biologically plausible pathway connects edaravone’s antioxidant activity to heparin cofactor deficiency’s coagulation-factor pathology. The high TxGNN score (99.47%) should therefore be interpreted as a knowledge-graph similarity signal rather than mechanistic validation. The same caveat applies to the second-ranked candidate, Factor V excess with spontaneous thrombosis (score 99.06%), where no literature or trial evidence links edaravone to thrombosis-pathway modulation either.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a TxGNN knowledge-graph score (L5, model prediction only) — there are no clinical trials, no published literature, and no established mechanistic link between edaravone’s antioxidant activity and this rare coagulation disorder. Combined with a Blocking-severity gap in TFDA label/safety data, this candidate does not meet the threshold to advance past S0.
To proceed, the following is needed:
- TFDA (or originating regulator) label with warnings/contraindications — currently a Blocking data gap
- Confirmed mechanism of action (DrugBank query) — currently a High-severity data gap
- Preclinical or mechanistic studies establishing a biological rationale linking free-radical scavenging to heparin cofactor 2 / coagulation-factor regulation
- Any case reports or observational data in rare coagulation disorders, given the ultra-low prevalence of both target conditions makes RCTs unlikely
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.